Tirzepatide and survodutide are both "dual agonists," but they pair GLP-1 with different second receptors: tirzepatide adds GIP, while survodutide adds glucagon. The other key difference is maturity — tirzepatide is FDA-approved with completed phase 3 trials, whereas survodutide is investigational.
At a glance
| Tirzepatide | Survodutide | |
|---|---|---|
| Drug class | GIP + GLP-1 dual agonist | Glucagon + GLP-1 dual agonist |
| Brand names | Mounjaro, Zepbound | None (investigational) |
| FDA status | Approved | Investigational |
| Second receptor | GIP | Glucagon |
| Also studied for | Diabetes, obesity, sleep apnea | Obesity, liver disease (MASH) |
| Evidence maturity | Completed phase 3 | Earlier-stage |
The bottom line
Bottom line: Tirzepatide is a finished, approved product (GIP + GLP-1) with a deep evidence base. Survodutide is an investigational glucagon/GLP-1 agent with promising obesity and liver-disease data but no approval. The glucagon mechanism is genuinely different, but a proven medicine and a candidate aren't interchangeable.
Frequently asked questions
What's the difference between tirzepatide and survodutide?
Both pair GLP-1 with a second receptor, but tirzepatide adds GIP while survodutide adds glucagon. Tirzepatide is FDA-approved; survodutide is investigational.
Is survodutide approved?
No. Survodutide is an investigational glucagon/GLP-1 dual agonist in clinical development. Tirzepatide is approved and available by prescription.
Why does survodutide target glucagon?
Glucagon receptor activity may increase energy expenditure and benefit liver fat, which is why survodutide is studied for both obesity and metabolic liver disease (MASH).
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. Peer-reviewed study
- Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021. Peer-reviewed study
- Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025. Peer-reviewed study
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023. Peer-reviewed study
- Zhao L, Cheng Z, Lu Y, et al. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA. 2024. Peer-reviewed study
- Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024. Peer-reviewed study
- Sanyal AJ, Bedossa P, Fraessdorf M, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024. Peer-reviewed study
- Bluher M, Rosenstock J, Hoefler J, et al. Dose-response effects of survodutide, a dual glucagon/GLP-1 receptor agonist, in people with type 2 diabetes: a randomised clinical trial. Diabetologia. 2024. Peer-reviewed study
- le Roux CW, Steen O, Lucas KJ, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024. Peer-reviewed study
- Kosiborod MN, Platz E, Wharton S, et al. Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial. JACC Heart Fail. 2024. Peer-reviewed study
- Kaya E, Yilmaz Y, Alkhouri N. Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction. Expert Opin Investig Drugs. 2024. Peer-reviewed study
- Lawitz EJ, Fraessdorf M, Neff GW, et al. Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis. J Hepatol. 2024. Peer-reviewed study